@article{ref1,
title="Report of experiences in the treatment of 16 cases of severe glycoside poisoning with digitalis antibody fragments (Fab)",
journal="Zeitschrift für Kardiologie",
year="1984",
author="Smolarz, A. and Roesch, E. and Lenz, Helge and Neubert, P. and Abshagen, U.",
volume="73",
number="2",
pages="113-119",
abstract="To date, 16 patients with severe glycoside poisoning have been treated with Fab as part of the clinical trial for efficacy and tolerance. The ages of the patients ranged from 4 to 77 years. In 13 cases, the substance was taken with suicidal intent. The following were considered to be indications for the use of Fab: the appearance of life-threatening arrhythmias as high-grade atrioventricular conduction disorders, multifocal ectopic beats, ventricular tachycardia, and relapsing ventricular fibrillation in 5 cases. Serum digoxin concentrations were between 3.8 and 78 ng/ml before the start of treatment. The amount of Fab administered was 240-800 mg, in the majority of cases 480 mg. Regression of the arrhythmias was seen in all patients during or shortly after the Fab infusion. There was a rapid fall in the free digoxin in the serum to levels that were no longer measurable and a marked rise in bound digoxin with a simultaneous intensive excretion of bound digoxin in the urine. Fab therapy is considered to be a major advance in the treatment of severe, previously fatal, glycoside poisoning. No notable side effects were observed, nor were there any allergic reactions to foreign protein.<p /><p>Language: de</p>",
language="de",
issn="0300-5860",
doi="",
url="http://dx.doi.org/"
}